A 68Ga-labeled version of the Affibody molecule, named [68Ga]Ga-DOTA-Cys-ATH001 has entered clinical phase 1 development as an imaging agent for detection of PDGFRβ in metabolic dysfunction-associated steatohepatitis (MASH) (NCT06562361)18, making its future validation in pulmonary fibrosis imaging a next step. This evidence concerns the gene PDGFRB and metabolic dysfunction-associated steatohepatitis.